Compare DAL & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAL | ONC |
|---|---|---|
| Founded | 1924 | 2010 |
| Country | United States | Switzerland |
| Employees | 78400 | 12000 |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.2B | 31.4B |
| IPO Year | 2004 | N/A |
| Metric | DAL | ONC |
|---|---|---|
| Price | $87.41 | $315.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 10 |
| Target Price | $79.26 | ★ $385.10 |
| AVG Volume (30 Days) | ★ 6.5M | 346.3K |
| Earning Date | 04-08-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | ★ 43.71 | N/A |
| EPS | ★ 2.00 | N/A |
| Revenue | ★ $41,244,000,000.00 | N/A |
| Revenue This Year | $3.47 | $723.76 |
| Revenue Next Year | $3.97 | $15.04 |
| P/E Ratio | ★ $44.39 | $614.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $51.23 | $253.95 |
| 52 Week High | $95.68 | $385.22 |
| Indicator | DAL | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 53.99 | 53.75 |
| Support Level | $80.64 | $304.87 |
| Resistance Level | $95.68 | $315.96 |
| Average True Range (ATR) | 2.20 | 8.16 |
| MACD | 0.03 | -0.43 |
| Stochastic Oscillator | 78.23 | 39.30 |
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke network, where it gathers and distributes passengers across the globe through its biggest hubs in Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta has historically earned most of its international revenue and profits from flying passengers over the Atlantic Ocean.
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.